| 1.345 -0.125 (-8.5%) | 12-12 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.15  |
1-year : | 2.51 |
| Resists | First : | 1.84 |
Second : | 2.15 |
| Pivot price | 1.54 |
|||
| Supports | First : | 1.34 |
Second : | 1.11 |
| MAs | MA(5) : | 1.49 |
MA(20) : | 1.61 |
| MA(100) : | 1.04  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.2 |
D(3) : | 26 |
| RSI | RSI(14): 40.6 |
|||
| 52-week | High : | 3.86 | Low : | 0.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RANI ] has closed below the lower bollinger band by 7.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 49.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.32 - 1.33 | 1.33 - 1.34 |
| Close: | 1.33 - 1.34 | 1.34 - 1.36 |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Mon, 24 Nov 2025
Rani Therapeutics to Participate in the Evercore Healthcare Conference - GlobeNewswire
Mon, 10 Nov 2025
RANI: Third Quarter Results - Yahoo Finance
Thu, 06 Nov 2025
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewswire
Wed, 05 Nov 2025
Rani Therapeutics: Oral Biologics Vision Still Has Early-Stage Risks (NASDAQ:RANI) - Seeking Alpha
Mon, 03 Nov 2025
Rani Therapeutics: Underdog to Top Performer? - StocksToTrade
Thu, 23 Oct 2025
Rani Therapeutics Holdings, Inc. Stock (RANI) Opinions on Billion-Dollar Chugai Deal - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 7.441e+007 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 119 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.004e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 418.2 % |
| Return on Equity (ttm) | -95.6 % |
| Qtrly Rev. Growth | 1.2e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 3e+006 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.37 |
| Dividend | 0 |
| Forward Dividend | 8.31e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|